Lunsekimig

Phase 3Small molecule

Lunsekimig is one of 111 small molecule programs targeting Chronic Obstructive Pulmonary Disease. It is currently in Phase 3.

Indications

Total Trials

Active Trials

110

Competitors

Pipeline

Status by Indication[3][1]

Indication

Chronic Obstructive Pulmonary DiseaseEnrolling by invitation

Chronic Rhinosinusitis With Nasal PolypsActive, not recruiting

Atopic DermatitisActive, not recruiting

AsthmaEnrolling by invitation

Chronic Obstructive Pulmonary DiseasePhase 3

Enrolling by invitation

Chronic Rhinosinusitis With Nasal PolypsPhase 2

Active, not recruiting

Atopic DermatitisPhase 2

Active, not recruiting

AsthmaPhase 2

Enrolling by invitation

Competition

Competitive Landscape

161 competitors in Asthma

#DrugCompanyPhaseTrials

Lunsekimig

Sanofi

Phase 3

3 2

Celexa

AbbVie

Preclinical

1 3

Arcoxia

Novartis

Preclinical

—4

Solu-Medrol

MMassachusetts Eye and Ear Infirmary

Preclinical

1 5

DUPIXENT

Regeneron

Preclinical

1 6

Paracetamol

GSK

Preclinical

1 7

Blood Withdrawn

Emergent BioSolutions

Preclinical

1 8

Aclidinium Bromide

AstraZeneca

Preclinical

—9

Blood Collection

AAssistance Publique - Hôpitaux de Paris

Preclinical

1 10

Lexapro

SShirley Ryan AbilityLab

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2027

Phase 2Active, not recruiting

Asthma

NCT06676319

Q1 2029

Phase 2Active, not recruiting

Chronic Rhinosinusitis With Nasal Polyps

NCT06914908

Q1 2030

Phase 3Recruiting

Chronic Obstructive Pulmonary Disease

NCT07190222

Phase 3Recruiting

Chronic Obstructive Pulmonary Disease

NCT07190209

Clinical

Trials by Indication[1]

Asthma3 trials

Dose Ranging Study of Lunsekimig Compared With Placebo-control in Adult Participants With Moderate-to-severe Asthma

Completed· Sanofi logo

Sanofi·Phase 2·NCT06102005·685 enrolled

A Randomized, Phase 2, Double-blind, Placebo-controlled, Parallel-group, 2-arm Study to Investigate the Efficacy, Safety, and Tolerability of Subcutaneous Lunsekimig (SAR443765) in Adult Participants With High-risk Asthma Who Are Not Currently Eligible for Biologic Treatment

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT06676319·556 enrolled

An Open Label Extension Study to Evaluate the Long-term Safety and Efficacy of Subcutaneous Lunsekimig in Adult Participants With Asthma Who Participated in Study DRI16762 or ACT18301

Enrolling by invitation· Sanofi logo

Sanofi·Phase 2·NCT06609239·900 enrolled

Chronic Obstructive Pulmonary Disease3 trials

A Phase 2b/Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07190222·942 enrolled

An Extension Study to Evaluate the Long-term Safety and Efficacy of Lunsekimig, Including Inhaled Corticosteroid Withdrawal, in Adults With Chronic Obstructive Pulmonary Disease (COPD) Who Completed Studies EFC18243 or EFC18244

Enrolling by invitation· Sanofi logo

Sanofi·Phase 3·NCT07793409·1,508 enrolled

A Phase 2b/Phase 3, Randomized, Double-blind, Placebocontrolled, Multicenter Study, to Investigate the Efficacy and Safety of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Recruiting· Sanofi logo

Sanofi·Phase 3·NCT07190209·942 enrolled

Chronic Rhinosinusitis With Nasal Polyps2 trials

A Proof-of-concept Study of Lunsekimig Compared With Placebo in Adults With Chronic Rhinosinusitis With Nasal Polyps

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT06454240·79 enrolled

A Single-arm Extension Study to Investigate the Long-term Safety, Tolerability, and Efficacy of Lunsekimig in Adult Participants With Inadequately Controlled Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) Who Completed a Previous Lunsekimig CRSwNP Clinical Study

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT06914908·71 enrolled

Atopic Dermatitis1 trial

A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis

Active, not recruiting· Sanofi logo

Sanofi·Phase 2·NCT06790121·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Lunsekimig. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Lunsekimig compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Lunsekimig. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sanofi company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: Sanofi

Lunsekimig

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q3 2027

Q1 2029

Q1 2030

Trials by Indication[1]

Asthma3 trials

Chronic Obstructive Pulmonary Disease3 trials

Chronic Rhinosinusitis With Nasal Polyps2 trials

Atopic Dermatitis1 trial

References

Drug Info

Quick Facts

Related News